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ABSTRACT
Interventions to prevent pneumonia in the intensive care unit should combine multiple measures
targeting the invasive devices, microorganisms and protection of the patient. Microbiological
investigation is useful for evaluating the quality of the respiratory sample, and permits early
modiﬁcation of the regimen in light of the microbiological ﬁndings. Once pneumonia develops, the
appropriateness of the initial antibiotic regimen is a vital determinant of outcome. Three questions
should be formulated: (1) is the patient at risk of acquiring methicillin-resistant Staphylococcus aureus, (2)
is Acinetobacter baumannii a problem in the institution, and (3) is the patient at risk of acquiring
Pseudomonas aeruginosa? Antibiotic therapy should be started immediately and must circumvent any
pathogen resistance mechanisms developed after previous antibiotic exposure. Therefore, antibiotic
choice should be institution-speciﬁc and patient-oriented.
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INTRODUCTION
Ventilator-associated pneumonia (VAP) repre-
sents 80% of episodes of hospital-associated
pneumonia, and the term is applied to episodes
that develop in intubated or tracheotomised
patients under mechanical ventilation. An arti-
ﬁcial airway is associated with a 21-fold
increase in the risk of developing pneumonia
[1]. Indeed, VAP is the most frequent nosoco-
mial infection in the intensive care unit (ICU)
and is responsible for more than half of antibi-
otic prescriptions in the ICU. Patients with VAP
have a high crude mortality rate, although the
question of whether these patients would sur-
vive in the absence of the complication is
controversial [2]. This article will update a
former review on VAP in adult patients [3],
placing particular emphasis on recent investiga-
tions. Immunocompromised patients and chil-
dren are beyond the scope of this review.
RISK FACTORS
In the National Nosocomial Infections Surveil-
lance (NNIS) system [4], rates of VAP varied from
ﬁve cases per 1000 ventilator-days in paediatric
patients to 16 cases per 1000 ventilator-days in
patients with thermal injury or trauma. Rates of
VAP are generally higher in surgical than in
medical ICU patients. Kollef [5] reported an
incidence of 21.6% in cardiothoracic patients,
compared with 14% in other surgical patients
and 9.3% in medical patients. The cumulative risk
of developing VAP is approximately 1% per day
of mechanical ventilation, but it is concentrated
within the ﬁrst days post-intubation [6].
Intubation is the most important risk factor for
developing nosocomial pneumonia [7]. Documen-
ted massive aspiration is associated with an
extremely high incidence of VAP [8]. Large study
populations provide the best opportunity to iden-
tify variables associatedwith a small increase in the
probability (i.e., odds ratios (ORs) < 2) as risk
factors for VAP.Aprospective cohort study of 1014
ventilated patients in Canada [9] identiﬁed the
following risk factors: burns (OR 5.09), trauma
(OR 5.0), central nervous system disease (OR 3.4),
witnessed aspiration (OR 3.25), respiratory disease
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(OR 2.79), cardiac co-morbidity (OR 2.72), venti-
lation in the last 24 h (OR 2.28), administration of
paralysing agents [1,57] and antibiotic exposure
(OR 0.37). In a matched cohort study [10] with
9080 patients in > 100 US hospitals, independent
risk factors associated with VAPweremale gender
(OR 1.58), trauma [1,75], and, interestingly, inter-
mediate deciles of severity upon admission
(OR 1.47–1.70 for deciles 31% to 80%). In low-
severity patients, the duration of exposure to
mechanical ventilation may not be long enough
for them to acquire VAP, whereas high-severity
patients may die before developing pneumonia.
The recent consensus conference on VAP [11]
concluded that risk factors vary, depending on
the duration of exposure to intubation. For exam-
ple, in a study [6] investigating pneumonia occur-
ring within 48 h after intubation, antibiotic
exposure had a protective effect (OR 0.29). In
contrast, antibiotic exposure signiﬁcantly
increased the risk of VAP (OR 1.42) for episodes
that developed later than 48 h. The study by Cook
et al. [9] supports this observation.
MORTALITY
Survival in patients with VAP is determined
primarily by the degree of severity of illness at
the time of diagnosis [12]. In a recent cohort study
[10], 842 patients with VAP (mean interval
between intubation and VAP of 3.3 days) were
matched with 2243 control subjects, and hospital
mortality did not differ (30.5% vs. 30.4%). This
does not rule out the possibility that in certain
subgroups of patients, such as patients with VAP
caused by Pseudomonas aeruginosa [13–15] or
methicillin-resistant Staphylococcus aureus (MRSA)
[16], mortality may have been extra attributable.
Nevertheless, patients with VAP [10] had signiﬁ-
cantly longer durations of mechanical ventilation
(10 extra days), ICU stay (6 extra days) and
hospital stay (11 extra days).
COSTS
The average excess hospital charges for nosoco-
mial pneumonia were estimated to be US$1255
per patient in 1982 in a study by Pinner et al. [17],
and US$2863 per patient in 1985 in another study
by Beyt et al. [18]. The largest US study [10]
performed to date estimated the cost of VAP per
patient in 1999 to be more than US$4000. Recently
[19], the attributable cost of VAP (after adjustment
for underlying severity) was approximately
US$11897.
PATHOPHYSIOLOGY AND
PREVENTION
There are only four routes though which bacteria
can reach the lower respiratory tract to cause
VAP: contiguous spread, haematogenous spread,
inhalation, and aspiration. Haematogenous or
contiguous routes of invasion are very rare.
Contamination of the ventilator circuits is univer-
sal and rarely has clinical implications. Therefore,
the ventilator circuit change interval does not
affect the incidence of VAP [20]. However,
improper manipulation of the circuits may allow
condensate from the warm humidiﬁed air that
ventilates patients to precipitate, and aerosolisa-
tion of bacteria is possible.
Aspiration is the main route by which bacteria
invade the lower airways and cause VAP. The
endotracheal tube holds the vocal cords open,
facilitating aspiration. Most patients are sedated,
or even paralysed, and thus cannot cough efﬁ-
ciently. The magnitude of aspiration of gastric
content is decreased in patients in a semi-upright
position, particularly when they are enterally fed
[21,22]. Once aspirated, the secretions pool above
the inﬂated endotracheal tube cuff. Maintenance
of the upper airway by early tracheotomy [23] or
effective drainage of subglottic secretions [24]
signiﬁcantly reduces the incidence of VAP. The
pressure in the endotracheal tube cuff changes
[25], deforming it and allowing the secretions to
be transported around the inﬂated cuff by capil-
lary action [24,25]. Cuff pressure should be
routinely monitored and maintained at above
25 cm of water, but under 30 cm of water to
prevent tracheal injury, which is essential to
ensure that subglottic drainage is effective [26].
Failure to avoid cuff leak is associated with
introduction of the organisms into the distal
airspaces. The defence mechanisms attempt to
eliminate them, and the outcome will depend on
the nature, bacterial burden and virulence of the
organisms, as well as on the biological status of
the host. If the tube is left in the trachea for several
days, an infected bioﬁlm develops on the inner
surface of the endotracheal tube [27].
Application of effective infection control
measures, including hand washing and micro-
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biological surveillance, is important for preven-
tion. Unfortunately, the rate of implementation of
evidence-based preventive measures [28] for VAP
is low, and the reasons for barriers to implement-
ing programmes are varied [29,30]. Educating
healthcare professionals and heightening their
awareness is the key to success [31–33]. Indeed, it
is vital that all healthcare professionals participate
in these programmes, and that these programmes
are customised to each ICU in order to ensure
continuous improvement in the provision of care
to critically ill intubated patients. Potential meas-
ures of control (Table 1) should focus on the
patient, the microorganisms, and the device.
AETIOLOGY
A report from The American Thoracic Society [34]
and a further report from France [35] described
the distribution of causative organisms for VAP
according to easily identiﬁable risk factors. These
studies suggested that classifying patients accord-
ing to prior duration of mechanical ventilation
and prior exposure or non-exposure to antibiotics
provided a rational basis for anticipating the
pathogens. Moreover, in a study comparing four
treatment sites [36], we concluded that the causes
of VAP varied markedly across different institu-
tions. This can be explained by differences in
patients’ demographics, strategies for prophy-
laxis, methods of diagnosis and, particularly,
local patterns of resistant organisms. A further
report from Namias et al. [37] conﬁrmed that
decisions regarding initial antibiotic choices
should consider local patterns of resistance.
Table 2 summarises the distribution of organ-
isms in some major studies [35,36,71] of VAP.
Haemophilus inﬂuenzae, Streptococcus pneumoniae
and methicillin-sensitive S. aureus (MSSA) should
be considered in patients without antibiotic expo-
sure. Compared to patients with VAP caused by
MSSA, cases associated with MRSA are often
older and signiﬁcantly more likely to have previ-
ous lung disease and to have undergone steroid
therapy and a longer period of mechanical ven-
tilation. Nearly all MRSA cases were exposed to
antibiotics [38]. Bacteraemia, shock and mortality
are signiﬁcantly higher in MRSA pneumonia. In a
study on VAP [39], non-fermenting Gram-negat-
ive bacilli accounted for 25% of the pathogens
isolated by protected specimen brush, but they
caused up to 80% of deaths related to pneumonia.
P. aeruginosa and MRSA are the leading patho-
gens associated with death from pneumonia.
Candida spp. are very commonly isolated. How-
ever, except in neutropenic or transplant patients,
yeasts are isolated from the respiratory tract in the
apparent absence of disease [40–42]. Other path-
ogens such as anaerobes [43], Legionella [44],
viruses [45] or Pneumocystis carinii are uncommon.
CLINICAL FEATURES
In the presence of clinical signs of sepsis (partic-
ularly fever and leukocytosis), the source of
infection should be investigated. Pneumonia is
the result of an invading organism overwhelming
lung defences. A local inﬂammatory response
follows, which is always manifested by purulent
respiratory secretions. In the absence of purulent
respiratory secretions, the diagnosis of VAP is
unlikely [46]. However, the only way to differen-
tiate tracheobronchitis from VAP is by the pres-
ence of a radiological opacity. Radiological
diagnosis is therefore mandatory for diagnosis.
Wunderink et al. [47] reported that no single
radiographic sign had a diagnostic accuracy
Table 1. Evidence-based measures to prevent ventilator-
asociated pneumonia (modiﬁed from Rello et al. [30],
Ricart et al. [31] and Zack et al. [32])
Strategy
Evidence
degree
(1) Protection of the patient
Use of gowns and gloves B
Adequate nutritional support C
Avoidance of gastric over-distension B
Postural changes B
Semi-recumbent positioning B
Limitation of stress-ulcer prophylaxis B
(2) Measures targeting microorganisms
Hand washing B
Chlorhexidine oral rinse B
Formal infection control programme C
Avoidance of unnecessary antibiotics C
Selective digestive decontamination A
Routine parenteral antibiotics
in comatose patients
B
(3) Interventions targeting the invasive devices
Adequate pressure of endotracheal cuff C
Removal of nasogastric ⁄ endotracheal tubes C
Humidiﬁcation with head moisture
exchangers
A
Drainage of condensate from
ventilator circuits
C
Subglottic drainage A
Oral intubation D
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above 68%. In patients with acute lung injury, this
correlation was particularly poor. In addition,
many other entities in intubated patients can
mimic VAP, such as atelectasis, pulmonary
oedema or thromboembolic disease [48,49].
The clinical pulmonary infection score (CPIS)
was created to predict the pre-test probability of
pneumonia [50]. It combines information con-
cerning body temperature, volume and appear-
ance of tracheal secretions, chest X-ray results,
white blood cell count, oxygenation and tracheal
aspirate culture. Serial measurements of CPIS [51]
have been used to monitor clinical resolution. A
persistent low score after 3 days of therapy in
patients in whom pneumonia was unlikely, based
on the CPIS, allowed a substantial reduction in
antibiotic use [49]. Limitations of the CPIS score
include the subjective (chest radiograph and
character of secretions) and retrospective (culture
of tracheal aspirate) nature of some variables, as
well as the arbitrary nature of element scoring.
Obviously, the value of the presence of tracheal
secretions should be different from that assigned
to the number of blood leukocytes or oxygenation
changes.
Pneumonia should be suspected in the pres-
ence of purulent respiratory secretions plus an
abnormal chest radiograph. In a critically ill
patient in this setting, empirical broad-spectrum
agents should be administered immediately.
Microbiological testing should be performed to
rule out other sources, and to identify the caus-
ative pathogen. This would permit prompt
modiﬁcation of therapy if there is resistance, or
de-escalation if the microorganisms are sensitive
to several agents. [52]
DIAGNOSIS
Decisions regarding the initiation of empirical
therapy can be improved if a cytospin is available
in the laboratory and initial antibiotic choices are
based on direct staining of respiratory samples.
Direct stains, available within 1 h, can be done
from protected specimen brush [43], bronchoal-
veolar lavage [53] or tracheal aspirates [54].
Mertens et al. [55] reported that fewer than 10%
of neutrophils in bronchoscopic samples is uni-
formly associated with negative cultures and
should be followed by a careful search for
alternative diagnoses. Moreover, the cellular
product of the sample can be used to evaluate
its quality. The presence of more than 1% of
epithelial cells in bronchoscopic samples suggests
heavy oropharyngeal contamination, making the
interpretation of cultures unreliable [56]. The level
may rise to ten squamous epithelial cells per low-
power ﬁeld (magniﬁcation, · 100) for tracheal
Table 2 Microorganisms causing
ventilator-associated pneumonia
(adapted from American Thoracic
Society [34], Trouillet et al. [35] and
Rello and Diaz [70])
Ibrahim et al.
[72] (n ¼ 420)
Trouillet et al.
[35] (n ¼ 245)
Rello et al.
[36] (n ¼ 301)
Aerobic Gram-positive
MRSA 81 (19.3%) 20 (8.2%) 10 (3.3%)
MSSA 62 (14.7%) 32 (13.1%) 38 (12.6%)
Streptococcus pneumoniae 6 (1.4%) 3 (1.2%) 25 (8.3%)
Other streptococci NR 33 (13.5%) 10 (3.3%)
Other NR 23 (19.4%) 24 (7.8%)
Aerobic Gram-negative
Pseudomonas aeruginosa 130 (30.9%) 39 (15.9%) 102 (33.9%)
Acinetobacter baumannii 16 (3.8%) 22 (9.0%) 38 (12.6%)
Klebsiella pneumoniae 25 (5.6%) 9 (3.7) 0 (0%)
Stenotrophomonas maltophilia 38 (9.0%) 6 (2.4%) 8 (2.6%)
Enterobacter spp. 43 (10.2%) 5 (2.0%) 44 (14.6%)
Proteus spp. 9 (2.1%) 7 (2.4%) 0 (0%)
Haemophilus inﬂuenzae 19 (4.5%) 15 (6.1%) 26 (8.6%)
Serratia spp. 13 (3.1%) 4 (1.6%) 0 (0%)
Escherichia coli 9 (2.2%) 8 (3.3%) NR
Other 19 (4.5%) 13 (5.3%) 23 (7.6%)
Anaerobic ﬂora NR 6 (2.4%) NR
Fungi 28 (6.6%) NR NR
Virus 5 (3.1%) NR NR
NR, not reported; MRSA, methicillin-resistant Stapylococcus aureus; MSSA,
methicillin-resistant Staphylococcus aureus.
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aspirates [54]. Morris et al. [54] reported that 85%
of tracheal aspirate specimens should be elimi-
nated from analysis because they contained more
than ten squamous epithelial cells per low-power
ﬁeld. Thus, the bacterial burden should be inter-
preted with consideration of the quality of the
sample, the speciﬁc clinical setting of the patient
(days of intubation and presence of co-morbidi-
ties), and the potential interference of antibiotics
in cultures [46,57].
Quantitative bronchoscopic samples are more
accurate [58], but are time-consuming, labour-
intensive and expensive, and may not be practical
for many laboratories [11,59]. Contraindications
exist, and management of the ventilator setting
should be by an expert, maintaining positive end-
expiratory pressures in hypoxaemic patients, as
detailed elsewhere [46]. If bronchoalveolar lavage
is performed to guide modiﬁcation of therapy in
patients with poor resolution [60], the impact on
outcome is minimal. In contrast [61], modiﬁcation
of the antimicrobial regimen, based on early
diagnostic testing (i.e., within 12 h of VAP suspi-
cion), has been associated with resolution of 63%
of episodes. What we have learned in the past
decade [57,59–62] is that avoiding delay in samp-
ling and starting therapy quickly is more import-
ant than the type of quantitative technique used.
RATIONAL MANAGEMENT OF
HOSPITAL-ACQUIRED PNEUMONIA
Septic shock and refractory hypoxaemia (often in
a context of organ dysfunction) are the most
frequent mechanisms of death. VAP can be
facilitated by previous lung damage caused by
over-distension as a result of using high tidal
volumes during mechanical ventilation or by
other non-infectious mechanisms [63]. Ventila-
tor-induced lung injury may also disseminate
local pulmonary infection [64] to the bloodstream,
producing bacteraemia, systemic inﬂammatory
responses and multiple organ dysfunction.
Delay in administration of effective therapy for
intubated patients with VAP is associated with
increases in mortality [61–63,65,66], morbidity,
and cost [67]. Optimising survival in patients with
VAP, aswell as costs, is based on prompt, adequate
therapy [68,69]. The key questions to address in a
speciﬁc patient with VAP are: (1) when to start
antibiotics, (2) how microbiological tests deter-
mine antibiotic changes (‘de-escalation’), (3) what
dose and duration, (4) what microorganisms
should be covered, and (5) which initial agent.
The choice of the initial antibiotic should be
based on avoiding agents previously used in
these patients [70], the patient’s co-morbidities
[34,71], length of hospitalisation [35,72] and local
sensitivities [36]. b-Lactam–b-lactamase inhibi-
tors, second-generation cephalosporins and
ertapenem are adequate as empirical monothera-
py in patients not having received previous
antibiotic therapy during the ﬁrst week of hospi-
talisation. However, in the presence of severe
sepsis or infections caused by P. aeruginosa or
MRSA, or when these pathogens are suspected,
initial narrow-spectrum antibiotic regimens
should not be used because they increase the risk
of death due to inadequate therapy if resistant
pathogens are implicated.
Table 3 summarises the points that determine
the management of VAP in our institution [71].
Knowledge of the local microbial epidemiology
and susceptibility patterns is crucial in the clini-
cian’s choice of antibiotics [36]. Heterogeneous
usage of antibiotics removes selective pressure
[73]. A heterogeneous pattern of prescription
reduces the likelihood of resistance [73,74] com-
pared with protocols that maintain a standard
option over a long period of time.
Most clinical trials, and some guidelines based
on experts’ opinions, recommend a minimum
course of 2 weeks of therapy for uncomplicated
respiratory infections [34]. Shorter antibiotic reg-
imens have been favoured by some authors to
reduce costs, adverse events and the emergence of
antibiotic-resistant pathogens [75]. Longer cour-
ses of antibiotics can increase costs and side-
effects, and select resistant phenotypes, and did
not prevent recurrences [76]. We recommend a
patient-based approach that has been recently
reported elsewhere [71].
The antibiotic penetration into lung tissues is
of vital importance in therapy. Septic ventilated
patients have increased volumes of distribution
that expose them to poor clinical resolution if
standard doses are prescribed. This suggests
that adequate therapy should no longer be
deﬁned on microbiological grounds alone [52].
The unacceptably high attributable mortality
rate of patients with pneumonia caused by S.
aureus treated with vancomycin [16,77,78], when
compared with cloxacillin [16,77] or linezolid
[78,79], illustrates this problem. This difference
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is probably due to the poor lung penetration of
vancomycin, with epithelial lining ﬂuid concen-
tration being lower than 4 mg ⁄L in 36% of
ventilated patients [80], and with a plasma to
epithelial lining ﬂuid drug penetration of 15%.
Similarly, in hospitals with imipenem-resistant
strains of Acinetobacter baumannii, the option of
using colistin is questionable. Because of the
low virulence of A. baumannii and the better
penetration of carbapenems to the lung, a
regimen of imipenem plus rifampin in pneu-
monia caused by imipenem-resistant A. bauman-
nii should be preferred [81]. If strains remain
susceptible to other agents, monotherapy is
adequate.
Optimal therapy depends on maintaining a
concentration above the MIC in lung tissue [71].
Opportunities for therapeutic improvement [82]
include optimising dosing, and considering phar-
macokinetics and pharmacodynamics and the
area under the inhibitory curve (AUIC). The
AUIC allows comparisons between drugs of
different classes, regardless of their pharmacoki-
netic and pharmacodynamic responses.
Strains of P. aeruginosa have different expres-
sions of virulence, inducing different degrees of
apoptosis and cytotoxicity [82]. Secretion of type
III proteins has been associated with very poor
outcomes (relapse or death) in patients with VAP
[83]. This suggests that antibodies against the
PcrV antigen might be incorporated into therapy
(and prevention) of VAP caused by P. aeruginosa.
Management of VAP in the year 2014 may
conceivably be based on a combination of newer
antibiotics [84], different principles of prescrip-
tion [82] and immunotherapy [85].
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